Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-03-12 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance. It is addressed to stock exchanges and signed by the company secretary. The document length is short (3084 characters) and it primarily serves as a compliance certificate rather than a full financial report or announcement. It does not contain financial statements or detailed report content. This fits the profile of a Regulatory Filing (RNS), which includes officer certifications and compliance confirmations.
2024-03-12 English
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Share Transfer Agents of the Company, ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. It is an announcement related to shareholding records and administrative procedures, not a financial report or meeting material. The document is short (1746 characters) and serves as a notification to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-11 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 39(3), which pertains to share certificate loss and related shareholder matters. The content is an announcement about a shareholder's lost share certificates and the company's intention to issue a Letter of Confirmation after formalities are completed. There is no financial data, no report attached or referenced as being published, no management discussion, no earnings information, or other report types. This is a regulatory announcement related to shareholding records and compliance disclosures. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-03-11 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding a Distribution and Promotion Agreement between AstraZeneca Pharma India Limited and Mankind Pharma Limited. It includes a press release detailing the partnership for distribution of a pharmaceutical product in India, along with an annexure providing specific details about the agreement. The document is dated March 11, 2024, and references compliance with a SEBI circular. There are no financial statements, earnings data, or management discussion of financial results. The content focuses on a business agreement and its strategic rationale, which aligns with a Capital/Financing Update or business partnership announcement rather than a financial report or regulatory filing about financial results or governance changes. Given the nature of the announcement about a significant business agreement impacting distribution and promotion, the most appropriate classification is Capital/Financing Update (CAP). The document length (9478 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2024-03-11 English
Please find enclosed the copy of press release in connection with a Distribution and Promotion Agreement entered into by the Company with Mankind Pharma Limited for the distribution of ....
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding a Distribution and Promotion Agreement between AstraZeneca Pharma India Limited and Mankind Pharma Limited. It includes a press release detailing the partnership for distribution of a pharmaceutical product in India, along with an annexure providing specific details about the agreement. The document does not contain financial statements, audit information, earnings data, or regulatory certifications. It is an announcement of a business agreement and partnership, which relates to capital or financing activities as it involves payment terms and distribution rights. The document length is 9478 characters, which is substantial but the content is clearly an update on a financing/distribution agreement rather than a full financial report or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-03-11 English
Copy of Newspaper Publication
Regulatory Filings
2024-03-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.